Payment overview · 2025
General Payments
$104.18
6 reported records · 5 companies
Healthcare provider profile · identity verified
Rocco Matthew Cambareri, MD
Allopathic & Osteopathic Physicians|Family Medicine · SYRACUSE, NY · NPI 1962815944
Verified facts
What the public records show
CMS Open Payments records show Rocco Matthew Cambareri, MD received $104.18 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.29 | 35.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.82 | 18.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.70 | 16.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.66 | 16.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.71 | 14.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $104.18 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 142 |
| Losartan Potassium | Losartan Potassium | 501 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 81 |
| Alprazolam | Alprazolam | 229 | 74 |
| Metformin Hcl Er | Metformin Hcl | 206 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 57 |
| Omeprazole | Omeprazole | 199 | 60 |
| Lisinopril | Lisinopril | 195 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 59 |
| Allopurinol | Allopurinol | 175 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 87 |
| Simvastatin | Simvastatin | 159 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 45 |
| Famotidine | Famotidine | 132 | 41 |
| Glipizide Er | Glipizide | 132 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 28 |
| Sertraline Hcl | Sertraline Hcl | 121 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 32 |
| Metformin Hcl | Metformin Hcl | 112 | 34 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 99 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 28 |
| Trazodone Hcl | Trazodone Hcl | 95 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 22 |
| Prednisone | Prednisone | 89 | 60 |
| Gabapentin | Gabapentin | 87 | 23 |
| Meloxicam | Meloxicam | 82 | 27 |
| Finasteride | Finasteride | 81 | 27 |
| Synthroid | Levothyroxine Sodium | 77 | 20 |
| Pregabalin | Pregabalin | 76 | 12 |
| Ezetimibe | Ezetimibe | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 17 |
| Furosemide | Furosemide | 69 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 18 |
| Ozempic | Semaglutide | 65 | 18 |
| Eliquis | Apixaban | 64 | 16 |
| Xarelto | Rivaroxaban | 64 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 46 |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 60 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 14 |
| Tramadol Hcl | Tramadol Hcl | 56 | 16 |
| Mirtazapine | Mirtazapine | 55 | suppressed |
| Potassium Chloride | Potassium Chloride | 54 | 20 |
| Celecoxib | Celecoxib | 52 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 12 |
| Carvedilol | Carvedilol | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 14 |
| Glipizide | Glipizide | 42 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 12 |
| Atenolol | Atenolol | 39 | 11 |
| Methylprednisolone | Methylprednisolone | 39 | 34 |
| Trulicity | Dulaglutide | 39 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Alendronate Sodium | Alendronate Sodium | 37 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | 12 |
| Donepezil Hcl | Donepezil Hcl | 37 | 13 |
| Spironolactone | Spironolactone | 37 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 11 |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Torsemide | Torsemide | 32 | 11 |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 21 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 13 |
| Amoxicillin | Amoxicillin | 20 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Fluconazole | Fluconazole | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Baclofen | Baclofen | 17 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104.18 · 6 records | Novo Nordisk Inc | FREESTYLE LIBRE 3, Ozempic, REXULTI, Rybelsus, WATCHMAN FLX, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error